Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
This Guide to Testing explores the limits of detection requirements for microbial testing of short-shelf-life products and sustainable endotoxin testing.
Join this webinar to hear about the latest RMM technology and how it aligns with UPS testing criteria.

List view / Grid view

Dr Mark Rutstein

 

Antibody-drug conjugates: paving the future of oncology clinical development - datopotamab deruxtecan
Antibody-drug conjugates: paving the future of oncology clinical development - datopotamab deruxtecan
article

Antibody-drug conjugates: paving the future of oncology clinical development

Dr Mark Rutstein, Senior Vice President, Head of Oncology Clinical…

26 October 2023 | By ,

Dr Mark Rutstein, Senior Vice President, Head of Oncology Clinical Development at Daiichi Sankyo, highlights key data about the company’s antibody-drug conjugate (ADC) being investigated for breast and lung cancer, and shares insight into why ADCs could replace current standards of care in oncology.